The NIHR Clinical Research Network, which supports researchers and clinicians across Imperial College and Imperial College Healthcare NHS Trust, have helped recruit the first global patient into a surgical study. The trial, which is being conducted by Mr Ahmed Ahmed, Clinical Senior Lecturer in Bariatric Surgery, will compare types of surgical stapler, to investigate whether a newer device will be more efficient and reduce complications for patients.
We are looking for healthy volunteers to part in an Imperial sponsored study called ‘Genetic Studies of the Heart and Circulation’, which aims to develop an atlas of the human heart to help scientists to determine the effect of different DNA and genes on heart shape and function. The research has been given ethical approval by the Research Ethics Committee (approval reference number 09/H0707/69).
Volunteers must be registered with a UK GP, have no heart-related health problems, and must be between the ages of 18 and 80. The study will involve some general lifestyle questions; height, weight and simple heart test function measurements; a three dimensional heart scan; and a blood (or saliva) sample. The appointment may take up to 90 minutes, and are held at Hammersmith Hospital, Du Cane Road, W12.
All participants will be reimbursed £25 and will receive a free CD of their scan.
The Clinical Trials Centre at St. Mary’s Hospital are looking for healthy HIV NEGATIVE male and female volunteers between the ages of 18-45, who are going to be around London for 6 months to take part in a Phase I clinical trial to develop a new vaccine.
If you are interested in wanting to take part please contact Stephen on free phone 0800 358 3001 or email: firstname.lastname@example.org for more information. Your time and travel for all visits will be reimbursed and you’ll receive up to £1100 over the course of the study.
This trial, led by Professor Robin Shattock in the Department of Medicine, forms part of the EU funded CUT’HIVAC project, which aims at assessing a new HIV vaccine strategy to prevent and control HIV infection based on transcutaneous and/or mucosal needle-free vaccination.
Study approved by Cambridge East Research Ethics Committee.